HOPO Therapeutics
HOPO Therapeutics
Home
About
Company
People
Careers
FAQ
Our Focus Areas
Radiological Hazards
Lead Poisoning
Metals in Medicine
Our Science
Discovery & Development
HOPO-101
Publications
News
Contact
contamination
From early prophylaxis to delayed treatment: Establishing the plutonium decorporation activity window of hydroxypyridinonate chelating agents
The potential consequences of a major radiological event are not only large-scale external radiation exposure of the population, but also uncontrolled dissemination of, and internal contamination with, radionuclides. When planning an emergency …
Biomimetic Actinide Chelators: An Update on the Preclinical Development of the Orally Active Hydroxypyridonate Decorporation Agents 3,4,3-LI(1,2-HOPO) and 5-LIO(Me-3,2-HOPO)
Cite
×